Merrimack to Present on Multiple Oncology Programs at the 2016 American Association for Cancer Research Annual Meeting

Oral presentation will introduce Merrimack's latest therapeutic candidate, MM-310, a novel EphA2 targeted nanoliposome for delivery of docetaxel

Presentations to include a late-breaking abstract describing in vitro and in vivo targeting effects of MM-302 in HER2 intermediate cancer cells

Mar 16, 2016, 16:45 ET from Merrimack Pharmaceuticals, Inc.

CAMBRIDGE, Mass., March 16, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data on its extensive oncology pipeline at the 2016 American Association for Cancer Research (AACR) Annual Meeting, April 16-20, 2016 at the Ernest N. Morial Convention Center, New Orleans, Louisiana. Of particular focus will be preclinical data on the latest novel therapeutic developed from Merrimack's nanoliposome platform and systems biology approach - MM-310, an ephrin receptor A2 (EphA2)-targeted nanoliposome delivering docetaxel.

EphA2 is a key receptor associated with poor prognosis and is shown to be overexpressed in several solid tumors including prostate, ovarian, gastric and lung cancer. In preclinical models, MM-310 has demonstrated that Merrimack's proprietary delivery platform provides controlled biodistribution and sustained exposure of the drug at the site of the tumor.  This design has shown improvement in antitumor activity while avoiding the hematologic toxicities common with docetaxel or the bleeding associated with a traditional antibody drug conjugate (ADC) format in preclinical models.

Merrimack will also present a late-breaking abstract describing in vitro and in vivo targeting effects of MM-302 in HER2 intermediate cancer cells as well as research on ONIVYDE® (irinotecan liposome injection) and other targeted therapies currently in development.

Oral presentation
MM-310: a novel EphA2 targeted nanoliposome for delivery of docetaxel

  • Session Title: Antibody-targeted Therapy
    Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale (Abstract #871)
    Sunday, April 17, 2016, 4:15 PM6:15 PM ET

Poster Sessions
MM-310: a novel EphA2 targeted nanoliposome for delivery of docetaxel

  • Session Title: Targeting the Microenvironment
    Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical Translation (Abstract #750, Poster Section 33)
    Sunday, April 17, 2016, 1:00 PM - 5:00 PM ET
  • Session Title: Drug Delivery
    Activity of an EphA2-targeted docetaxel nanoliposome in pancreatic patient-derived models as monotherapy and in combination with gemcitabine (Abstract #2069, Poster Section 15)
    Monday, April 18, 2016, 1:00 PM - 5:00 PM ET
  • Session Title: Therapeutics
    MM-310, a novel EphA2-targeted docetaxel nanoliposome (Abstract #3912, Poster Section 21)
    Tuesday, April 19, 2016, 1:00 PM - 5:00 PM ET

MM-398 (ONIVYDE® (irinotecan liposome injection) or "Nal-IRI"): a novel encapsulation of irinotecan in a liposomal formulation

  • Session Title: Drug Delivery
    Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors (Abstract #2075, Poster Section 15)
    Monday, April 18, 2016, 1:00 PM - 5:00 PM ET
  • Session Title: Targeted Therapy
    Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer (Abstract #4830, Poster Section 20)
    Wednesday, April 20, 2016, 8:00 AM - 12:00 PM ET

MM-302: a novel HER2 targeted liposomal doxorubicin

  • Session Title: Late-Breaking Research: Cancer Chemistry
    HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo (Abstract #LB-061, Poster Section 12)
    Sunday, April 17, 2016, 1:00 PM5:00 PM ET

MM-141 (istiratumab):  a monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR

  • Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
    Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models (Abstract #1209, Poster Section 15)
    Monday, April 18, 2016, 8:00 AM - 12:00 PM ET

MM-151: an oligoclonal therapeutic consisting of a mixture of 3 fully human monoclonal antibodies designed to bind and inhibit signaling of the epidermal growth factor receptor (EGFR) 

  • Session Title: New Drugs, Therapeutic Targets, and Treatment Approaches
    MM-151 elicits broad and unique inhibition of cells harboring EGFR extracellular domain mutations —results of multiscale experiments with genome-edited cell lines (Abstract #2148, Poster Section 18)
    Monday, April 18, 2016, 1:00 PM - 5:00 PM ET

Companion Therapeutics:

  • Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
    A network biology screen reveals ligand-receptor pathway connections and resistance mechanisms to RTK-directed therapies in cancer cells (Abstract #1199, Poster Section 15)
    Monday, April 18, 2016, 8:00 AM - 12:00 PM ET

Preclinical Research:

  • Session Title: Targeting Protein Kinases, Death Pathways, and the Tumor Microenvironment
    Design and engineering of TRAIL fusion proteins for cancer therapy (Abstract #3842, Poster Section 19)
    Tuesday, April 19, 2016, 1:00 PM - 5:00 PM ET

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contacts:
Media Contact
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

Investor Contact:
Geoffrey Grande, CFA 
617-441-7602
ggrande@merrimack.com

SOURCE Merrimack Pharmaceuticals, Inc.



RELATED LINKS

http://www.merrimackpharma.com